stoxline Quote Chart Rank Option Currency Glossary
  
Scilex Holding Company (SCLX)
8.31  0.05 (0.61%)    02-13 16:00
Open: 8.46
High: 8.7001
Volume: 53,903
  
Pre. Close: 8.26
Low: 8.15
Market Cap: 71(M)
Technical analysis
2026-02-13 4:47:03 PM
Short term     
Mid term     
Targets 6-month :  13.47 1-year :  16.15
Resists First :  11.53 Second :  13.82
Pivot price 8.72
Supports First :  7.82 Second :  6.5
MAs MA(5) :  8.53 MA(20) :  9.31
MA(100) :  15.57 MA(250) :  12.55
MACD MACD :  -1.3 Signal :  -1.4
%K %D K(14,3) :  13.7 D(3) :  16.7
RSI RSI(14): 33.4
52-week High :  34.27 Low :  3.59
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SCLX ] has closed above bottom band by 26.5%. Bollinger Bands are 77.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.7 - 8.75 8.75 - 8.79
Low: 8.04 - 8.09 8.09 - 8.13
Close: 8.24 - 8.31 8.31 - 8.38
Company Description

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Headline News

Wed, 04 Feb 2026
Scilex Expands Strategic Equity Stake in Quantum Scan - The Globe and Mail

Mon, 02 Feb 2026
Scilex Holding Signs Multiple Financing Agreements With Q Scan - TradingView

Fri, 30 Jan 2026
Scilex Holding Company Invests $20 Million in Quantum Scan Holdings, Inc. to Boost Medical Technology Development - Quiver Quantitative

Sat, 10 Jan 2026
Not Many Are Piling Into Scilex Holding Company (NASDAQ:SCLX) Stock Yet As It Plummets 26% - simplywall.st

Wed, 17 Dec 2025
Retail investors invested in Scilex Holding Company (NASDAQ:SCLX) copped the brunt of last week's US$12m market cap decline - simplywall.st

Mon, 08 Dec 2025
Scilex Holding Company's (NASDAQ:SCLX) top owners are retail investors with 57% stake, while 24% is held by private companies - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 0 (M)
Shares Float 7 (M)
Held by Insiders 3.65e+006 (%)
Held by Institutions 17.5 (%)
Shares Short 134 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.5916e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 766.2 %
Return on Equity (ttm) -87.5 %
Qtrly Rev. Growth 4.036e+007 %
Gross Profit (p.s.) -19.5
Sales Per Share 0
EBITDA (p.s.) 2.0058e+007
Qtrly Earnings Growth -40.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 24 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.39
Stock Dividends
Dividend 0
Forward Dividend 171350
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android